Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

References

• Le Gales-Camus C, Waxman A. Fighting obesity: clarification from World Health Organization. Br Med J 2004;329:53–4
   Google Scholar
• McIntyre AM. Burden of illness review of obesity: are the true costs realised? J R Soc Health 1998;118:76–84
   PubMedGoogle Scholar
• Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583–9
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004;55:589–612
   Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691–701
   PubMed Web of Science ®Google Scholar
• Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968–77
   PubMed Web of Science ®Google Scholar
• Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136–41
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;6:283–96
   Google Scholar
• Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for critical appraisal. Diabetes Care 2005;28:2289–304
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel III. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, final report. Circulation 2002;106:3143–421
   PubMed Web of Science ®Google Scholar
• Liberopoulos E, Tsouli S, Mikhailidis D, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7 (in press)
   Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065–74
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Elisaf MS. Diagnosis of the metabolic syndrome: which definition should we use? Hell J Cardiol 2005;46:258–62
   PubMedGoogle Scholar
• Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14:308–17
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15–22
   Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269–76
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87–98
   PubMedGoogle Scholar
• Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin-resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779–85
   Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154–60
   PubMed Web of Science ®Google Scholar
• Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513–7
   PubMed Web of Science ®Google Scholar
• Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am 2004;33:545–55
   PubMed Web of Science ®Google Scholar
• UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241–7
   PubMed Web of Science ®Google Scholar
• Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003;25:1107–22
   PubMed Web of Science ®Google Scholar
• Bairaktari ET, Seferiadis KI, Elisaf MS. Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther 2005;10:45–54
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25:1713–21
   PubMed Web of Science ®Google Scholar
• Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003;91: 961–4
   Google Scholar
• Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002;20:2257–67
   PubMed Web of Science ®Google Scholar
• Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004;20:1393–401
   PubMed Web of Science ®Google Scholar
• Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001;87:827–31
   PubMed Web of Science ®Google Scholar
• Mittendorfer B, Ostlund Jr RE, Patterson BW, et al. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599–604
   PubMedGoogle Scholar
• Tolentino MC, Ferenczi A, Ronen L, et al. Combination of gemfibrozil and orlistat for treatment of combined hyperlipidaemia with predominant hypertriglyceridaemia. Endocr Pract 2002;8:208–12
   PubMedGoogle Scholar
• Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005;12:1931–45
   PubMed Web of Science ®Google Scholar
• Wysocki J, Belowski D, Kalina M, et al. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther 2004;42:212–7
   PubMed Web of Science ®Google Scholar
• Idzior-Walus B, Sieradzki J, Rostworowski W, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000;30:871–8
   Google Scholar
• Kiortsis DN, Elisaf MS. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Fundam Clin Pharmacol 2001;15:401–3
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride levels. J Cardiovasc Pharmacol Ther 2004;9:27–33
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457–68
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients [European Multicentre Orlistat Study Group]. Lancet 1998;352:167–72
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, Di Girolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J Am Med Assoc 1999;281:235–42
   PubMed Web of Science ®Google Scholar
• Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes – a systematic review. Obes Rev 2004;5:43–50
   PubMedGoogle Scholar
• Sartorio A, Lafortuna CL, Vangeli V, et al. Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr 2001;55:865–9
   PubMed Web of Science ®Google Scholar
• Noakes M, Keogh JB, Foster PR, et al. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005;81:1298–306
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642–50
   PubMedGoogle Scholar
• Brook RD, Bard RL, Glazewski L, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004;93:1012–6
   PubMed Web of Science ®Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288–94
   PubMed Web of Science ®Google Scholar
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123–8
   PubMed Web of Science ®Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002;25: 1033–41
   Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Miltiadous G, Bairaktari E, et al. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002;57:407–8
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Nishtar S, Lumb PJ, et al. Impaired renal function and atherosclerosis in a Pakistani cohort. Curr Med Res Opin 2005;21:1201–7
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589–99
   Google Scholar
• Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347
   Google Scholar
• Daskalopoulou SS, Tzovaras V, Mikhailidis DP, et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11 (in press)
   Google Scholar
• Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003; 42:321–5
   PubMed Web of Science ®Google Scholar
• Hepburn AL, Kaye SA, Feher MD. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol 2003;22:73–6
   Google Scholar
• Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421–7
   PubMed Web of Science ®Google Scholar
• Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131–4
   PubMedGoogle Scholar
• Ganotakis E, Tsimihodimos V, Bairaktari E, et al. Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 2002;165:187–8
   PubMed Web of Science ®Google Scholar
• Rizos E, Bairaktari E, Ganotakis E, et al. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002;7:219–26
   PubMedGoogle Scholar
• Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease: a clinical-histological study. J Hepatol 2004;41:751–7
   PubMed Web of Science ®Google Scholar